Search Results - "Caplin, M E"

Pollution and respiratory disease: can diet or supplements help? A review by Whyand, T, Hurst, J R, Beckles, M, Caplin, M E

“…Pollution is known to cause and exacerbate a number of chronic respiratory diseases. The World Health Organisation has placed air pollution as the world's…”
Get full text

A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms by Khan, M S, Luong, T V, Watkins, J, Toumpanakis, C, Caplin, M E, Meyer, T

“…Background: The aim of this study was to compare mitotic count (MC) and Ki-67 proliferation index as prognostic markers in pancreatic and midgut neuroendocrine…”
Get full text

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) by Ramage, John K, Ahmed, A, Ardill, J, Bax, N, Breen, D J, Caplin, M E, Corrie, P, Davar, J, Davies, A H, Lewington, V, Meyer, T, Newell-Price, J, Poston, G, Reed, N, Rockall, A, Steward, W, Thakker, R V, Toubanakis, C, Valle, J, Verbeke, C, Grossman, A B

“…These guidelines update previous guidance published in 2005. They have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour…”
Get more information

Long‐term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel) by Khan, M. S., El‐Khouly, F., Davies, P., Toumpanakis, C., Caplin, M. E.

“…Aliment Pharmacol Ther 2011; 34: 235–242 Summary Background  Somatostatin analogues are the mainstay of therapy for malignant carcinoid syndrome. There is…”
Get full text

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours by Turner, N C, Strauss, S J, Sarker, D, Gillmore, R, Kirkwood, A, Hackshaw, A, Papadopoulou, A, Bell, J, Kayani, I, Toumpanakis, C, Grillo, F, Mayer, A, Hochhauser, D, Begent, R H, Caplin, M E, Meyer, T

“…Background: The role of chemotherapy for neuroendocrine tumours remains controversial and there is no standard regimen. Method: We report the outcome for a…”
Get full text

Carcinoid tumour of the appendix by Goede, A. C., Caplin, M. E., Winslet, M. C.

“…Background: Appendiceal carcinoid tumours are found in 0·3–0·9 per cent of patients undergoing appendicectomy. Controversy exists over the management following…”
Get full text

Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies by Srirajaskanthan, R, Watkins, J, Marelli, L, Khan, K, Caplin, M E

“…Somatostatin and dopamine receptors are both G-protein-coupled receptors. Somatostatin receptor (SSTR) expression in neuroendocrine tumours has been well…”
Get more information

Long‐term results of patients with malignant carcinoid syndrome receiving octreotide LAR by TOUMPANAKIS, C., GARLAND, J., MARELLI, L., SRIRAJASKANTHAN, R., SOH, J., DAVIES, P., BUSCOMBE, J., CAPLIN, M. E.

“…Summary Background  Octreotide LAR is an established treatment for malignant carcinoid syndrome. However, studies with large number of patients and long…”
Get full text

Epidermal Growth Factor Receptor Expression and Activation in Neuroendocrine Tumours by Shah, T., Hochhauser, D., Frow, R., Quaglia, A., Dhillon, A. P., Caplin, M. E.

“…Epidermal growth factor receptor (EGFR) is expressed in many cancers and is associated with poor prognosis. EGFR activation pathways have been well…”
Get full text

Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis by Srirajaskanthan, R, Dancey, G, Hackshaw, A, Luong, T, Caplin, M E, Meyer, T

“…Angiogenesis is an essential process in the development and growth of tumours. There are a large number of angiogenic mediators including the angiopoietin…”
Get full text

A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer by Meyer, T, Caplin, M.E, Palmer, D.H, Valle, J.W, Larvin, M, Waters, J.S, Coxon, F, Borbath, I, Peeters, M, Nagano, E, Kato, H

“…Abstract Aim To evaluate the combination of the gastrin antagonist Z-360 and gemcitabine for advanced pancreatic cancer. Methods Previously untreated patients…”
Get full text

A review of thymic tumours by Srirajaskanthan, R, Toubanakis, C, Dusmet, M, Caplin, M.E

“…Summary Tumours of the thymus are uncommon and are generally regarded as being indolent. Whilst this is often true of thymomas; thymic adenocarcinoma and…”
Get full text

Phase II Study of Anti–Gastrin-17 Antibodies, Raised to G17DT, in Advanced Pancreatic Cancer by BRETT, B. T, SMITH, S. C, CAPLIN, M. E, BOUVIER, C. V, MICHAELI, D, HOCHHAUSER, D, DAVIDSON, B. R, KURZAWINSKI, T. R, WATKINSON, A. F, VAN SOMEREN, N, POUNDER, R. E

“…The prognosis for advanced pancreatic cancer remains poor. Gastrin acts as a growth factor for pancreatic cancer. We describe the first study of the…”
Get full text

Sandostatin LAR (long‐acting octreotide acetate) for malignant carcinoid syndrome: a 3‐year experience by Garland, J., Buscombe, J. R., Bouvier, C., Bouloux, P., Chapman, M. H., Chow, A. C., Reynolds, N., Caplin, M. E.

“…Summary Background : Somatostatin analogues are the best therapy for controlling the symptoms of malignant carcinoid syndrome. Octreotide acetate given as…”
Get full text

Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours by SRIRAJASKANTHAN, R., TOUMPANAKIS, C., MEYER, T., CAPLIN, M. E.

“…Summary Background  Gastroenteropancreatic neuroendocrine tumours (GEP NETs) are relatively uncommon tumours that occur anywhere within the gastrointestinal…”
Get full text

Surgical management and palliative treatment in bronchial neuroendocrine tumours: A clinical study of 45 patients by Srirajaskanthan, R, Toumpanakis, C, Karpathakis, A, Marelli, L, Quigley, A.M, Dusmet, M, Meyer, T, Caplin, M.E

“…Abstract Bronchial neuroendocrine tumours account for 1–2% of all lung cancers; they are thought to arise from the neuroendocrine cells located in the…”
Get full text

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids by Caplin, M.E., Baudin, E., Ferolla, P., Filosso, P., Garcia-Yuste, M., Lim, E., Oberg, K., Pelosi, G., Perren, A., Rossi, R.E., Travis, W.D., Bartsch, Detlief, Capdevila, Jaume, Costa, Frederico, Cwikla, Jaroslaw, de Herder, Wouter, Delle Fave, Gianfranco, Eriksson, Barbro, Falconi, Massimo, Ferone, Diego, Gross, David, Grossman, Ashley, Ito, Tetsuhide, Jensen, Robert, Kaltsas, Gregory, Kelestimur, Fahrettin, Kianmanesh, Reza, Knigge, Ulrich, Kos-Kudla, Beata, Krenning, Eric, Mitry, Emmanuel, Nicolson, Marianne, O'Connor, Juan, O'Toole, Dermot, Pape, Ulrich-Frank, Pavel, Marianne, Ramage, John, Raymond, Eric, Rindi, Guido, Rockall, Andrea, Ruszniewski, Philippe, Salazar, Ramon, Scarpa, Aldo, Sedlackova, Eva, Sundin, Anders, Toumpanakis, Christos, Vullierme, Marie-Pierre, Weber, Wolfgang, Wiedenmann, Bertram, Zheng-Pei, Zeng

“…Pulmonary carcinoids (PCs) are rare tumors. As there is a paucity of randomized studies, this expert consensus document represents an initiative by the…”
Get full text

α-Fetoprotein and human chorionic gonadotrophin-β as prognostic markers in neuroendocrine tumour patients by Shah, T, Srirajaskanthan, R, Bhogal, M, Toubanakis, C, Meyer, T, Noonan, A, Witney-Smith, C, Amin, T, Bhogal, P, Sivathasan, N, Warner, B, Hochhauser, D, Caplin, M E

“…Serum chromogranin A is the most useful general and prognostic tumour marker available for neuroendocrine tumour (NET) patients. The role of other tumour…”
Get full text

Carcinoid tumour by Caplin, Martyn E, Buscombe, John R, Hilson, Andrew J, Jones, Alison L, Watkinson, Anthony F, Burroughs, Andrew K

“…Carcinoid tumours are often indolent asymptomatic tumours. However, a small but significant proportion are malignant and difficult to manage. Multiple…”
Get full text

A comparison of CellCollector with CellSearch in patients with neuroendocrine tumours by Mandair, D, Vesely, C, Ensell, L, Lowe, H, Spanswick, V, Hartley, J A, Caplin, M E, Meyer, T

Get full text